Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 89 entries
Sorted by: Best Match Show Resources per page
Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease.

Hepatology research : the official journal of the Japan Society of Hepatology

Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Asano T, Yoshizawa K, Okubo T, Chuganji Y, Aizawa Y, Iio E, Tanaka Y, Iwakiri K.
PMID: 28225572
Hepatol Res. 2017 Oct;47(11):1165-1173. doi: 10.1111/hepr.12879. Epub 2017 Apr 12.

AIM: To evaluate the efficacy and safety of daclatasvir and asunaprevir combined therapy in genotype 1b chronic hepatitis C patients with non-dialysis chronic kidney disease (CKD).METHODS: In a multicenter collaborative study, 249 patients received 60 mg daclatasvir (NS5A inhibitor)...

Cite
Kondo C, Atsukawa M, Tsubota A, et al. Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatol Res. 2017;47(11):1165-1173doi: 10.1111/hepr.12879.
Kondo, C., Atsukawa, M., Tsubota, A., Shimada, N., Abe, H., Asano, T., Yoshizawa, K., Okubo, T., Chuganji, Y., Aizawa, Y., Iio, E., Tanaka, Y., & Iwakiri, K. (2017). Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatology research : the official journal of the Japan Society of Hepatology, 47(11), 1165-1173. https://doi.org/10.1111/hepr.12879
Kondo, Chisa, et al. "Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,11 (2017): 1165-1173. doi: https://doi.org/10.1111/hepr.12879
Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Asano T, Yoshizawa K, Okubo T, Chuganji Y, Aizawa Y, Iio E, Tanaka Y, Iwakiri K. Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatol Res. 2017 Oct;47(11):1165-1173. doi: 10.1111/hepr.12879. Epub 2017 Apr 12. PMID: 28225572.
Copy Download .nbib Format: NLM
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C.

Clinical pharmacology in drug development

Eley T, He B, Huang SP, Li W, Pasquinelli C, Rodrigues AD, Grasela DM, Bertz RJ.
PMID: 27121936
Clin Pharmacol Drug Dev. 2013 Oct;2(4):316-27. doi: 10.1002/cpdd.52. Epub 2013 Aug 16.

Asunaprevir (BMS-650032, ASV) is a potent, selective hepatitis C virus (HCV) NS3 protease inhibitor in clinical evaluation for chronic hepatitis C treatment. ASV pharmacokinetics were evaluated in four single- and multiple-ascending-dose studies in healthy subjects or subjects with HCV...

Cite
Eley T, He B, Huang SP, et al. Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C. Clin Pharmacol Drug Dev. 2013;2(4):316-27doi: 10.1002/cpdd.52.
Eley, T., He, B., Huang, S. P., Li, W., Pasquinelli, C., Rodrigues, A. D., Grasela, D. M., & Bertz, R. J. (2013). Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C. Clinical pharmacology in drug development, 2(4), 316-27. https://doi.org/10.1002/cpdd.52
Eley, Timothy, et al. "Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C." Clinical pharmacology in drug development vol. 2,4 (2013): 316-27. doi: https://doi.org/10.1002/cpdd.52
Eley T, He B, Huang SP, Li W, Pasquinelli C, Rodrigues AD, Grasela DM, Bertz RJ. Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C. Clin Pharmacol Drug Dev. 2013 Oct;2(4):316-27. doi: 10.1002/cpdd.52. Epub 2013 Aug 16. PMID: 27121936.
Copy Download .nbib Format: NLM
Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir.

World journal of clinical cases

Suga T, Sato K, Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S, Kusano M, Yamada M.
PMID: 26677451
World J Clin Cases. 2015 Dec 16;3(12):1005-10. doi: 10.12998/wjcc.v3.i12.1005.

A 66-year-old, interferon-ineligible, treatment-naive man who was diagnosed with chronic hepatitis C due to hepatitis C virus genotype 1b began combination therapy with daclatasvir and asunaprevir. On day 14 of treatment, hepatic reserve and renal function deterioration was observed,...

Cite
Suga T, Sato K, Yamazaki Y, et al. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World J Clin Cases. 2015;3(12):1005-10doi: 10.12998/wjcc.v3.i12.1005.
Suga, T., Sato, K., Yamazaki, Y., Ohyama, T., Horiguchi, N., Kakizaki, S., Kusano, M., & Yamada, M. (2015). Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World journal of clinical cases, 3(12), 1005-10. https://doi.org/10.12998/wjcc.v3.i12.1005
Suga, Takayoshi, et al. "Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir." World journal of clinical cases vol. 3,12 (2015): 1005-10. doi: https://doi.org/10.12998/wjcc.v3.i12.1005
Suga T, Sato K, Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World J Clin Cases. 2015 Dec 16;3(12):1005-10. doi: 10.12998/wjcc.v3.i12.1005. PMID: 26677451; PMCID: PMC4677081.
Copy Download .nbib Format: NLM
Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals.

Hepatology research : the official journal of the Japan Society of Hepatology

Kurata H, Uchida Y, Kouyama JI, Naiki K, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S.
PMID: 28872737
Hepatol Res. 2018 Feb;48(3):E372-E378. doi: 10.1111/hepr.12977. Epub 2017 Sep 25.

A 40-year-old male patient with virologic relapse after daclatasvir plus asunaprevir therapy for a serogroup 1 hepatitis C virus (HCV) infection visited our hospital for retreatment. Virologic examinations revealed that a genotype 2b HCV strain carrying both NS3-S122N /...

Cite
Kurata H, Uchida Y, Kouyama JI, et al. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res. 2017;48(3):E372-E378doi: 10.1111/hepr.12977.
Kurata, H., Uchida, Y., Kouyama, J. I., Naiki, K., Nakazawa, M., Ando, S., Nakao, M., Motoya, D., Sugawara, K., Inao, M., Imai, Y., Nakayama, N., Tomiya, T., & Mochida, S. (2018). Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatology research : the official journal of the Japan Society of Hepatology, 48(3), E372-E378. https://doi.org/10.1111/hepr.12977
Kurata, Hayato, et al. "Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,3 (2018): E372-E378. doi: https://doi.org/10.1111/hepr.12977
Kurata H, Uchida Y, Kouyama JI, Naiki K, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res. 2018 Feb;48(3):E372-E378. doi: 10.1111/hepr.12977. Epub 2017 Sep 25. PMID: 28872737.
Copy Download .nbib Format: NLM
Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients.

World journal of hepatology

Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K.
PMID: 28469810
World J Hepatol. 2017 Apr 18;9(11):544-550. doi: 10.4254/wjh.v9.i11.544.

AIM: To survey the efficacy and safety of dual therapy with daclatasvir and asunaprevir in the elderly hepatitis C virus (HCV) patients multicentricity.METHODS: Interferon-ineligible/intolerant patients and non-responders to previous pegylated-interferon/ribavirin therapy with chronic HCV genotype 1b infection were enrolled....

Cite
Tarao K, Tanaka K, Nozaki A, et al. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol. 2017;9(11):544-550doi: 10.4254/wjh.v9.i11.544.
Tarao, K., Tanaka, K., Nozaki, A., Sato, A., Ishii, T., Komatsu, H., Ikeda, T., Komatsu, T., Matsushima, S., & Oshige, K. (2017). Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World journal of hepatology, 9(11), 544-550. https://doi.org/10.4254/wjh.v9.i11.544
Tarao, Kazuo, et al. "Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients." World journal of hepatology vol. 9,11 (2017): 544-550. doi: https://doi.org/10.4254/wjh.v9.i11.544
Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol. 2017 Apr 18;9(11):544-550. doi: 10.4254/wjh.v9.i11.544. PMID: 28469810; PMCID: PMC5395803.
Copy Download .nbib Format: NLM
"Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline.

Hepatology research : the official journal of the Japan Society of Hepatology

Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S.
PMID: 28239934
Hepatol Res. 2017 Dec;47(13):1397-1407. doi: 10.1111/hepr.12882. Epub 2017 Apr 19.

AIMS: The therapeutic efficacy of daclatasvir/asunaprevir was inferior in patients with non-structural protein 5A (NS5A)-R30Q mutant hepatitis C virus strains at baseline, compared with those with wild-type strains, even though the half maximal effective concentration of NS5A inhibitors was...

Cite
Uchida Y, Kouyama JI, Naiki K, et al. "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res. 2017;47(13):1397-1407doi: 10.1111/hepr.12882.
Uchida, Y., Kouyama, J. I., Naiki, K., Sugawara, K., Inao, M., Imai, Y., Nakayama, N., & Mochida, S. (2017). "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatology research : the official journal of the Japan Society of Hepatology, 47(13), 1397-1407. https://doi.org/10.1111/hepr.12882
Uchida, Yoshihito, et al. ""Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,13 (2017): 1397-1407. doi: https://doi.org/10.1111/hepr.12882
Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S. "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res. 2017 Dec;47(13):1397-1407. doi: 10.1111/hepr.12882. Epub 2017 Apr 19. PMID: 28239934.
Copy Download .nbib Format: NLM
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.

Therapeutics and clinical risk management

Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G.
PMID: 25061308
Ther Clin Risk Manag. 2014 Jun 26;10:493-504. doi: 10.2147/TCRM.S66731. eCollection 2014.

According to the World Health Organization, approximately 150 million people worldwide are chronic carriers of hepatitis C virus (HCV). HCV infection can evolve into cirrhosis of the liver and its complications, which are ultimately responsible for more than 350,000...

Cite
Gentile I, Buonomo AR, Zappulo E, et al. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014;10:493-504doi: 10.2147/TCRM.S66731.
Gentile, I., Buonomo, A. R., Zappulo, E., Minei, G., Morisco, F., Borrelli, F., Coppola, N., & Borgia, G. (2014). Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Therapeutics and clinical risk management, 10493-504. https://doi.org/10.2147/TCRM.S66731
Gentile, Ivan, et al. "Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection." Therapeutics and clinical risk management vol. 10 (2014): 493-504. doi: https://doi.org/10.2147/TCRM.S66731
Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014 Jun 26;10:493-504. doi: 10.2147/TCRM.S66731. eCollection 2014. PMID: 25061308; PMCID: PMC4079632.
Copy Download .nbib Format: NLM
Restoration of natural killer cell activity by interferon-free direct-acting antiviral combination therapy in chronic hepatitis C patients.

Hepatology research : the official journal of the Japan Society of Hepatology

Nakamura I, Furuichi Y, Sugimoto K.
PMID: 29732688
Hepatol Res. 2018 Oct;48(11):855-861. doi: 10.1111/hepr.13186. Epub 2018 Jun 03.

AIM: Interferon-free direct-acting antiviral (DAA) therapy is an effective treatment for chronic hepatitis C (CH(C)) patients. Activity of natural killer (NK) cells was reported to be impaired in patients with hepatitis C virus infection. The aim of this study...

Cite
Nakamura I, Furuichi Y, Sugimoto K. Restoration of natural killer cell activity by interferon-free direct-acting antiviral combination therapy in chronic hepatitis C patients. Hepatol Res. 2018;48(11):855-861doi: 10.1111/hepr.13186.
Nakamura, I., Furuichi, Y., & Sugimoto, K. (2018). Restoration of natural killer cell activity by interferon-free direct-acting antiviral combination therapy in chronic hepatitis C patients. Hepatology research : the official journal of the Japan Society of Hepatology, 48(11), 855-861. https://doi.org/10.1111/hepr.13186
Nakamura, Ikuo, et al. "Restoration of natural killer cell activity by interferon-free direct-acting antiviral combination therapy in chronic hepatitis C patients." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,11 (2018): 855-861. doi: https://doi.org/10.1111/hepr.13186
Nakamura I, Furuichi Y, Sugimoto K. Restoration of natural killer cell activity by interferon-free direct-acting antiviral combination therapy in chronic hepatitis C patients. Hepatol Res. 2018 Oct;48(11):855-861. doi: 10.1111/hepr.13186. Epub 2018 Jun 03. PMID: 29732688.
Copy Download .nbib Format: NLM
Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b.

Value in health regional issues

McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Broglio K, Kamae I, Quintana M, Berry SM, Kobayashi M, Inoue S, Tang A, Kumada H.
PMID: 29702919
Value Health Reg Issues. 2014 May;3:136-145. doi: 10.1016/j.vhri.2014.04.005. Epub 2014 May 21.

OBJECTIVES: Japan has one of the highest endemic rates of hepatitis C virus (HCV) infection. Treatments in Japan are currently limited to interferon-alfa-based regimens, which are associated with tolerability and efficacy issues. A novel regimen combining two oral HCV...

Cite
McEwan P, Ward T, Webster S, et al. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value Health Reg Issues. 2014;3:136-145doi: 10.1016/j.vhri.2014.04.005.
McEwan, P., Ward, T., Webster, S., Yuan, Y., Kalsekar, A., Broglio, K., Kamae, I., Quintana, M., Berry, S. M., Kobayashi, M., Inoue, S., Tang, A., & Kumada, H. (2014). Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value in health regional issues, 3136-145. https://doi.org/10.1016/j.vhri.2014.04.005
McEwan, Phil, et al. "Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b." Value in health regional issues vol. 3 (2014): 136-145. doi: https://doi.org/10.1016/j.vhri.2014.04.005
McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Broglio K, Kamae I, Quintana M, Berry SM, Kobayashi M, Inoue S, Tang A, Kumada H. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value Health Reg Issues. 2014 May;3:136-145. doi: 10.1016/j.vhri.2014.04.005. Epub 2014 May 21. PMID: 29702919.
Copy Download .nbib Format: NLM
Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen.

Hepatology research : the official journal of the Japan Society of Hepatology

Ikeda H, Watanabe T, Shimizu H, Hiraishi T, Kaneko R, Baba T, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H, Okuse C, Iwabuchi S, Suzuki M, Itoh F.
PMID: 29504692
Hepatol Res. 2018 Sep;48(10):802-809. doi: 10.1111/hepr.13074. Epub 2018 May 04.

AIM: The therapeutic benefit of adding ribavirin (RBV) to 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) for patients who experienced failure of a previous nonstructural protein (NS) 5A inhibitor-containing regimen is unclear.METHODS: A total of 29 genotype 1b HCV patients who...

Cite
Ikeda H, Watanabe T, Shimizu H, et al. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018;48(10):802-809doi: 10.1111/hepr.13074.
Ikeda, H., Watanabe, T., Shimizu, H., Hiraishi, T., Kaneko, R., Baba, T., Takahashi, H., Matsunaga, K., Matsumoto, N., Yasuda, H., Okuse, C., Iwabuchi, S., Suzuki, M., & Itoh, F. (2018). Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatology research : the official journal of the Japan Society of Hepatology, 48(10), 802-809. https://doi.org/10.1111/hepr.13074
Ikeda, Hiroki, et al. "Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,10 (2018): 802-809. doi: https://doi.org/10.1111/hepr.13074
Ikeda H, Watanabe T, Shimizu H, Hiraishi T, Kaneko R, Baba T, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H, Okuse C, Iwabuchi S, Suzuki M, Itoh F. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018 Sep;48(10):802-809. doi: 10.1111/hepr.13074. Epub 2018 May 04. PMID: 29504692.
Copy Download .nbib Format: NLM
Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals.

Clinical and translational gastroenterology

Nagao Y, Kimura K, Kawahigashi Y, Sata M.
PMID: 27388424
Clin Transl Gastroenterol. 2016 Jul 07;7(7):e179. doi: 10.1038/ctg.2016.37.

OBJECTIVES: Oral lichen planus (OLP) is one of the extrahepatic manifestations of hepatitis C virus (HCV) infection. Presently developed interferon (IFN)-free direct-acting antivirals (DAAs) used to treat HCV infection have low side effect profiles and high efficacy. However, there...

Cite
Nagao Y, Kimura K, Kawahigashi Y, et al. Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clin Transl Gastroenterol. 2016;7(7):e179doi: 10.1038/ctg.2016.37.
Nagao, Y., Kimura, K., Kawahigashi, Y., & Sata, M. (2016). Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clinical and translational gastroenterology, 7(7), e179. https://doi.org/10.1038/ctg.2016.37
Nagao, Yumiko, et al. "Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals." Clinical and translational gastroenterology vol. 7,7 (2016): e179. doi: https://doi.org/10.1038/ctg.2016.37
Nagao Y, Kimura K, Kawahigashi Y, Sata M. Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clin Transl Gastroenterol. 2016 Jul 07;7(7):e179. doi: 10.1038/ctg.2016.37. PMID: 27388424; PMCID: PMC5543481.
Copy Download .nbib Format: NLM
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.

Hepatology research : the official journal of the Japan Society of Hepatology

Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.
PMID: 27943523
Hepatol Res. 2017 Oct;47(11):1127-1136. doi: 10.1111/hepr.12851. Epub 2017 Jan 31.

AIM: Hepatitis C virus (HCV) infection is a risk factor for end-stage renal disease, renal graft failure, and hemodialysis patient mortality. However, the efficacy of direct-acting antiviral therapy for HCV-infected patients with renal impairment is unclear. Additionally, the promising...

Cite
Suda G, Nagasaka A, Yamamoto Y, et al. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. Hepatol Res. 2017;47(11):1127-1136doi: 10.1111/hepr.12851.
Suda, G., Nagasaka, A., Yamamoto, Y., Furuya, K., Kumagai, K., Kudo, M., Terashita, K., Kobayashi, T., Tsunematsu, I., Yoshida, J., Meguro, T., Kimura, M., Ito, J., Umemura, M., Izumi, T., Tsunematsu, S., Sato, F., Tsukuda, Y., Nakai, M., Sho, T., Natsuizaka, M., Morikawa, K., Ogawa, K., Sakamoto, N. (2017). Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. Hepatology research : the official journal of the Japan Society of Hepatology, 47(11), 1127-1136. https://doi.org/10.1111/hepr.12851
Suda, Goki, et al. "Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,11 (2017): 1127-1136. doi: https://doi.org/10.1111/hepr.12851
Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. Hepatol Res. 2017 Oct;47(11):1127-1136. doi: 10.1111/hepr.12851. Epub 2017 Jan 31. PMID: 27943523.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 89 entries